GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research ...

GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...

GSK plc and the University of Oxford (Oxford) announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer ...